Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+biologics

95 Results

Sort By:

CRISPR/Cas9 and Tumor-Specific Guide RNAs as a Specific and Selective Cancer Cell Killing Biologic Platform

Value Proposition: Specific targeting of mutations can treat any cancer with the specified mutations. Selective cell killing spares healthy tissue while eliminating cancer cells. Pan-cancer efficacy as guide RNAs are developed to target a wide breadth of cancer-specific mutations. Integration into host cells prevents healthy cells from transforming...

Published: 5/14/2024 | Inventor(s): James Eshleman, Selina Shiqing Teh, Kirsten Bowland, Nicholas Roberts

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Research Tools > Nucleic Acids

Cell-Permeable Protein Therapeutic for Pain and Itch

Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...

Published: 5/9/2024 | Inventor(s): Hao-Jui Weng, Xinzhong Dong

Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain

Transgenic Fungi that Kill Malaria Parasites in Mosquitoes

Invention novelty: This material is a transgenic fungus which targets the sporozoites that cause malaria in the salivary glands of mosquitoes. The fungus is taken up by direct contact with the mosquito and inhibits Plasmodium development. Value Proposition: Unmodified, Metarhizium anisopliae kills mosquitoes slowly. If mosquitoes are infected by the...

Published: 5/9/2024 | Inventor(s): Raymond St. Leger, Angray Kang, Weiguo Fang, Marcelo Jacobs-Lorena

Keywords(s): Biologics, Disease Indication, Disease Management System, Healthcare Management, Infectious Diseases, Malaria, Operations Management, Parasitic Infections, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Computers, Electronics & Software > Clinical Management, Technology Classifications > Computers, Electronics & Software > Healthcare IT, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Computers, Electronics & Software, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections

Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells

Unmet NeedGlobal revenue from the cytokine therapeutics market was valued at approximately $16.5 billion in 2018, and cytokine immunotherapy is a promising field of anti-cancer treatments for a broad range of cancer types. In particular, interleukin-2 (IL-2) therapy is shown to stimulate anti-cancer immunity. However, IL-2 activates contradictory immune...

Published: 5/9/2024 | Inventor(s): Jamie Spangler, Jakub Tomala, Michael Leff, Seth Ludwig, Elissa Leonard, Marek Kovar, Jirina Kovarova

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics

Bioreducible Poly(beta-amino ester)s for siRNA Delivery

C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...

Published: 5/9/2024 | Inventor(s): Kristen Kozielski, Stephany Tzeng, Jordan Green

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Albumin-Flt3L Fusion Protein to Enhance Anti-Tumor Immunity and Antigen-specific T-cell Cytotoxicity

Unmet Need: Active immunotherapy, such as anti-PD-1/PD-L1 and anti-CTLA-4 checkpoint blockage, involves the administration of molecules to mobilize host immune cells to recognize and kill tumors. Proper presentation of tumor antigens through antigen presenting cells is a prerequisite to elicit a potent immune response. Current strategies enhance antigen...

Published: 5/9/2024 | Inventor(s): T.c. Wu, Chien-Fu Hung, Brandon Lam

Keywords(s): Biologics, Cancers, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Research Instrument, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Clinical and Disease Specializations > Immunology, Technology Classifications, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Targets

Antisense oligonucleotide therapy and biomarker assay for C9ORF72 hexanucleotide expansion disorders

Therapy to Treat and Assay to Monitor Neurodegenerative Disease JHU REF: [C12195]Invention novelty: This technology is the use of antisense oligonucleotides (ASO) as a therapeutic for specific neurodegenerative diseases. The technology could also be used in development of a biomarker assay to monitor the efficacy of the ASO therapy. Value Proposition: Current...

Published: 5/9/2024 | Inventor(s): Christopher Donnelly, C. Bennett, Susan Freier, Rita Sattler, Jeffrey Rothstein

Keywords(s): Amyotrophic Lateral Sclerosis, Assay, Biologics, Clinical Diagnostics, CNS and Neurological Disorders, Dementia, Disease Indication, In Vitro Diagnostics, Neurodegeneration, Nucleic Acid, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia, Clinical and Disease Specializations > Neurology > Neurodegeneration

Radiolabeled Thapsigargin Analogs Incorporated into Protease Activated Prodrugs

Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA, hK2 or PSMA-specific peptide prodrugs that become...

Published: 5/9/2024 | Inventor(s): Soren Christensen, John Isaacs, Samuel Denmeade

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Nanoparticle Modification of Human Adipose-derived Mesenchymal Stem Cells for Brain Cancer and Other Neurological Diseases

Human Adipose-derived Mesenchymal Stem Cells can be engineered to synthesize and release anti-tumor proteins and therefore can be used as “Trojan Horses”. The inventors have created a novel technology which encompasses a solution containing biodegradable, polymeric nanoparticles that is combined with Freshly-extracted Adipose Tissue (F.A.T.) (from...

Published: 5/9/2024 | Inventor(s): Jordan Green, Alfredo Quinones-Hinojosa

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, CNS and Neurological Disorders, Disease Indication, Drug Delivery Vehicle, Glioma, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Mutant Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH): A Novel Anticancer Therapeutic for Solid Malignancies

Unmet Need: One of the hallmarks of cancer cells is metabolic reprogramming for faster metabolism and cell growth. For example, increased glycolysis has long been known to be part of cancer cells’ biochemical adaptation. One of the key enzymes of glycolysis is glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which catalyzes the first step of energy...

Published: 5/9/2024 | Inventor(s): Shanmugasundaram Ganapathy-Kanniappan

Keywords(s): Biologics, Cancers, Disease Indication, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities

1 2 3 4 5 6 7 8 9 10